

**CONFIDENTIAL**

**BRCAAnalysis<sup>®</sup> Rearrangement Test**  
**Full Gene BRCA1-BRCA2 Large Rearrangement Analysis Result**

<b>PHYSICIAN</b>  <b>John Smith, MD</b> <b>Comprehensive Medical Center</b> <b>1100 Grand Ave</b> <b>Away, GA 12345</b>	<b>SPECIMEN</b>  Specimen: <b>Blood</b> Draw date: <b>Aug 01, 2010</b> Accession date: <b>Aug 02, 2010</b> Report Date: <b>Jun 22, 2011</b>	<b>PATIENT</b>  Name: <b>Doe, Jane</b> Date of Birth: <b>April 1, 1492</b> Patient ID: <b>000000</b> Gender: <b>Female</b> Accession #: <b>000-BLD</b> Requisition #: <b>000000</b>
--	--	--

**Test Results and Interpretation**

**NO LARGE REARRANGEMENT DETECTED**

<u>Test Performed:</u> <i>BRCA1</i> full gene rearrangement	<u>Result:</u> No Mutation Detected	<u>Interpretation:</u> No Mutation Detected
<i>BRCA2</i> full gene rearrangement	No Mutation Detected	No Mutation Detected

Analysis consists of a comprehensive rearrangement test of both BRCA1 and BRCA2 by quantitative PCR analysis. The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

No large rearrangement (duplication or deletion) was found in the BRCA1 or BRCA2 genes in this individual by quantitative PCR analysis. Quantitative PCR analysis is designed to identify duplications and deletions involving the promoter region and any exons of BRCA1 and BRCA2. This test is not designed to detect mutations identified by sequence analysis nor other unusual structural abnormalities in these genes.

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

\_\_\_\_\_

Director Name Here  
Qualifications Here

Director Name Here  
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.